Video

Early Promise of Radiation Plus PCV in Patients With Low-Grade Glioma

Author(s):

Erica Bell, PhD
Conference|ASCO Annual Meeting

Erica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.

Erica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.

Related Videos
VK Gadi, MD, PhD
Komal Jhaveri, MD, FACP
Mark Pegram, MD
David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute
Rene Adam, MD, PhD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Mikkael A. Sekeres, MD, professor, medicine, chief, Division of Hematology, Leukemia Section, the University of Miami Sylvester Comprehensive Cancer Center
Hetty E. Carraway, MD, MBA
Tycel Phillips, MD, MPH
Mazyar Shadman, MD, MPH
Related Content
Erin Frances Cobain, MD
June 8th 2024

MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment
May 10th 2021

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment

Mansoor Raza Mirza, MD
June 7th 2024

Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer

Fernando Cotait Maluf, MD
June 7th 2024

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

Charlene Mantia, MD, of Dana-Farber Cancer Institute
June 6th 2024

Nivolumab/Cabozantinib Combination Prolongs Treatment-Free Survival in Advanced RCC

Roger Li, MD
June 6th 2024

High CR Rate in NMIBC Is Maintained by Cretostimogene Grenadenorepvec Plus Pembrolizumab